tirzepatide dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology InVivoSIM GIPR/GLP‑1R Dual Agonist (Tirzepatide

[6] Another consideration involves renal function

This method is straightforward and can be easily done at home with the right training and supplies

Trends in Endocrinology & Metabolism , 29(6), 423-435

The article's comparison table lists tirzepatide as a dual GLP-1 and GIP agonist with a half-life of roughly five days, against semaglutide as a GLP-1 receptor agonist with a subcutaneous half-life of about seven days

Experts believe it is because these medications slow digestion

Known as GLP-1s (Glucagon-like Peptide agonists), they've become the world's best-selling prescription medications, but they're also some of the most expensive